|
|
|
Insider
Information: |
Bonney Michael W |
Relationship: |
Director |
City: |
Lexington |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
11 |
|
Direct
Shares |
1,699,363 |
|
Indirect Shares
|
231,000 |
|
|
Direct
Value |
$4,626,616 |
|
|
Indirect Value
|
$689,703 |
|
|
Total
Shares |
1,930,363 |
|
|
Total
Value |
$5,316,319 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
0.0%
|
-23.2%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
NPS Pharmaceuticals Inc |
NPSP |
Director |
2015-02-21 |
0 |
2005-05-17 |
0 |
Premium* |
|
H&Q Healthcare Investors |
HQH |
Director |
2014-06-24 |
1,860 |
2012-03-09 |
0 |
Premium* |
|
Tekla Life Sciences Investors |
HQL |
Director |
2014-06-24 |
2,388 |
2014-06-24 |
0 |
Premium* |
|
Tekla Healthcare Opportunities F... |
THQ |
Director |
2014-07-28 |
5,000 |
2014-07-28 |
0 |
Premium* |
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2023-12-27 |
16,029 |
2023-12-27 |
4,000 |
Premium* |
|
Tekla World Healthcare Fund |
THW |
Director |
2015-08-17 |
10,917 |
2015-08-17 |
0 |
Premium* |
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
Sarepta Therapeutics Inc |
SRPT |
Director |
2020-02-28 |
9,126 |
2018-03-05 |
0 |
Premium* |
|
Dianthus Therapeutics Ord Shs |
DNTH |
Director |
2018-06-25 |
215,346 |
2018-06-25 |
0 |
Premium* |
|
Kaleido Biosciences, Inc. |
KLDO |
Executive Chair, Direc... |
2019-03-04 |
1,426,196 |
2019-03-04 |
225,000 |
Premium* |
|
Bristol-Myers Squibb Co |
BMY |
Director |
2021-06-13 |
12,501 |
2021-06-13 |
2,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NPSP |
NPS Pharmaceuticals Inc |
Director |
|
2005-05-17 |
4 |
B |
$12.95 |
$51,800 |
D/D |
4,000 |
4,000 |
2.39 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Director |
|
2012-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
15,225 |
15,225 |
0 |
- |
|
HQH |
H&Q Healthcare Investors |
Director |
|
2012-03-09 |
4 |
B |
$15.80 |
$10,268 |
D/D |
650 |
650 |
2.39 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Director |
|
2013-02-07 |
4 |
AS |
$8.74 |
$46,541 |
D/D |
(5,325) |
13,900 |
0 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Director |
|
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
15,225 |
19,225 |
0 |
- |
|
HQH |
H&Q Healthcare Investors |
Director |
|
2014-06-24 |
4 |
OE |
$25.04 |
$27,591 |
D/D |
1,102 |
1,860 |
0 |
- |
|
HQL |
Tekla Life Sciences Inves... |
Director |
|
2014-06-24 |
4 |
OE |
$19.75 |
$28,815 |
D/D |
1,459 |
2,388 |
0 |
- |
|
THQ |
Tekla Healthcare Opportun... |
Director |
|
2014-07-28 |
4 |
B |
$20.00 |
$100,000 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Director |
|
2015-02-21 |
4 |
D |
$46.00 |
$639,400 |
D/D |
(13,900) |
0 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Director |
|
2015-05-12 |
4 |
B |
$112.16 |
$224,320 |
I/I |
2,000 |
2,000 |
2.1 |
- |
|
THW |
Tekla World Healthcare Fu... |
Director |
|
2015-08-17 |
4 |
B |
$18.35 |
$200,294 |
D/D |
10,917 |
10,917 |
2.39 |
- |
|
CELG |
Celgene Corp |
Director |
|
2016-03-03 |
4 |
B |
$103.01 |
$206,028 |
I/I |
2,000 |
2,000 |
2.1 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Director |
|
2016-03-09 |
4 |
B |
$58.36 |
$116,720 |
I/I |
2,000 |
4,000 |
2.1 |
- |
|
CELG |
Celgene Corp |
Director |
|
2017-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
375 |
375 |
0 |
- |
|
SRPT |
Sarepta Therapeutics Inc |
Director |
|
2018-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,418 |
3,418 |
0 |
- |
|
CELG |
Celgene Corp |
|
|
2018-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
300 |
675 |
0 |
- |
|
CELG |
Celgene Corp |
|
|
2018-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
375 |
1,050 |
0 |
- |
|
DNTH |
Dianthus Therapeutics Ord... |
Director |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
21,847 |
215,346 |
0 |
- |
|
KLDO |
Kaleido Biosciences, Inc. |
Executive Chair |
|
2019-02-28 |
4 |
B |
$13.95 |
$999,493 |
D/D |
71,520 |
1,008,523 |
2.81 |
- |
|
KLDO |
Kaleido Biosciences, Inc. |
Executive Chair |
|
2019-03-04 |
4 |
A |
$0.00 |
$0 |
I/I |
225,000 |
225,000 |
0 |
- |
|
KLDO |
Kaleido Biosciences, Inc. |
Executive Chair |
|
2019-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
417,673 |
1,426,196 |
0 |
- |
|
SRPT |
Sarepta Therapeutics Inc |
Director |
|
2019-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
1,633 |
5,051 |
0 |
- |
|
CELG |
Celgene Corp |
|
|
2019-06-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
484 |
1,534 |
0 |
- |
|
CELG |
Celgene Corp |
|
|
2019-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
300 |
1,834 |
0 |
- |
|
CELG |
Celgene Corp |
|
|
2019-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
375 |
2,209 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|